麻豆传媒

Dr. Brian Anderson is a Harvard-trained physician-scientist, innovator, and digital health expert. Dr. Anderson鈥檚 focus is on the use of information technology in support of emerging clinical decision support (CDS) models and the provision of safe, effective, patient-centered care. 
While at Athenahealth, where he led the Informatics Department, Dr. Anderson launched a new model of CDS leveraging Artificial Intelligence (AI). He has served on several national health information technology committees in partnership with the Office of the National Coordinator (ONC). 
At MITRE, Dr. Anderson works on mCODE, a standardized data language and interoperability model for cancer research and treatment, as well as architecting, implementing, and analyzing health information systems for the Centers for Medicare and Medicaid Services (CMS), the Department of Health and Human Services (HHS), and the Department of Veterans Affairs (VA). He also sits on the ONC鈥檚 Health Information Technology Advisory Committee.
Dr. Anderson has written in the Journal of Precision Medicine and spoken at the Precision Medicine Summit and HIMSS19. 

Dr. Larry Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former president and director of the Fred Hutchinson Cancer Research Center in Seattle. For more than four decades, he has led some of the most significant advances in medicine, including the development of safe and effective antivirals for herpes, HIV and hepatitis infections. An international expert in the design and testing of vaccines, he is helping to formulate a global, strategic response to COVID-19.

Earlier this year, he responded to the sudden emergence of COVID-19 by redirecting his energies to speed the development of antiviral medications and vaccines against SARS-CoV-2, the virus responsible for the pandemic. He is building strategic collaborations among academic institutions, government health leaders and the pharmaceutical industry to test future COVID-19 vaccines and find ways to manufacture and distribute enough doses to immunize as many as 4 billion people.

Dr. Corey is drawing on his expertise as a co-founder, in 1998, of the HIV Vaccine Trials Network. Headquartered at Fred Hutch in Seattle, it is the world鈥檚 largest publicly funded collaboration focused on development of vaccines to prevent HIV/AIDS.

Dr. Corey's teaching and mentoring interests include virology, viral immunology and development of novel therapies for viral infections. His current research projects include:

- Spatial and functional characterization of tissue resident immune responses at the site of herpesvirus or HIV infection
- Development of immunotherapies for HSV and HIV infection; including CAR T cells for treatment for HIV infection
- Spatial dynamics and function of adoptively transferred or vaccine induced T cells
- Characterization of tissue-based memory B cells and the role antibody effector responses play in chronic viral infections
- Use of monoclonal antibodies for the prevention of viral infections

In addition to his role as president and director emeritus at Fred Hutch, Dr. Corey is a member of the Center's Vaccine and Infectious Disease, Clinical Research, and Public Health Sciences Divisions.  He is also a Professor, Medicine and Laboratory Medicine at the University of Washington, and Principal Investigator at the HIV Vaccine Trials Network (HVTN). 

Dr. Ostrosky-Zeichner is a professor of medicine and epidemiology, the chair of the Division of Infectious Diseases, the Vice-Chair of Medicine for Healthcare Quality, and the director of the Laboratory of Mycology Research, at McGovern Medical School (a part of UTHealth Houston). He also serves medical director for epidemiology and antimicrobial stewardship for Memorial Hermann Texas Medical Center and UT Physicians. He also coordinated the CoVID-19 response for UTHealth and its affiliated hospitals and clinics. Dr. Ostrosky-Zeichner obtained his medical degree from Universidad Nacional Autonoma de Mexico. He completed his internal medicine residency at Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, and his infectious diseases fellowship at the University of Texas Medical School at Houston and MD Anderson Cancer Center combined fellowship program. Dr. Ostrosky-Zeichner is a fellow of the American College of Physicians, the Infectious Diseases Society of America, the Society of Healthcare Epidemiology of America, and the Academy of the European Confederation of Medical Mycology. He is a Senior Editor for the Journal of Antimicrobial Chemotherapy, as well as an editorial board member of Antimicrobial Agents and Chemotherapy and Clinical Infectious Diseases. He is Vice President of the Mycoses Study Group and Educational Consortium and a Board Member of the International Immunocompromised Host Society. He is also a past chair of the Infectious Diseases Society of America Standards and Practice Guidelines Committee and has been a consultant to the US FDA and CDC. He has advanced training and experience in medical mycology, healthcare epidemiology, emerging infections, antimicrobial stewardship, general and transplant infectious diseases, and healthcare quality and has published over 155 peer-reviewed articles on those topics.

Dr. Faisal Masud serves as Board Member, Houston Methodist Board of Directors, and Medical Director of Center for Critical Care at Houston Methodist Hospital System overseeing 8 hospitals ICU鈥檚 and V-ICU. He also serves as Vice-Chair for Quality and Patient Safety, the Associate Quality Officer, and Medical Director, Cardiovascular Intensive Care Unit, Methodist DeBakey Heart & Vascular Center. He is Professor of Clinical Anesthesiology, Weill Cornell Medical College, Professor of Anesthesiology at Houston Methodist Institute of Academic Medicine, and Professor in the Department of Acute & Continuing Care at UT-Houston. He received his training at Duke University Medical Center and Cleveland Clinic Foundation.

Among his many awards is Presidential Gold Medal. He has been the recipient of the Golden Apple Award for Excellence in Teaching four times, the Dean H. Morrow Resident Mentor Award in 2001, and the most prestigious Fulbright & Jaworski Faculty Excellence Award in Educational Leadership. He was elected a member of the Academy of Distinguished Educators at Baylor College of Medicine. He received the Association of Professional in Infection Control (APIC) National award for Heroes in Infection Prevention 2010. He is also a recipient of the Overstreet Award for exemplifying the best of the medical profession.

Dr. Masud's leadership resulted in great improvements in patient care and clinical outcomes, in patient safety & quality, sepsis control, central line infections, ventilator associated pneumonia, surgical site infections, blood transfusions, pharmacy etc. resulting hundreds of lives saved and millions of dollar in cost savings.

His focus is on improving healthcare in underdeveloped health systems in less developed countries and has been doing volunteer work to improve healthcare in vulnerable areas for many years. He is also the Board Member of Shifa USA a Houston based charitable organization providing free medical and dental care, women shelter, etc.

He has many research projects, publications and is an invited faculty at multiple local, state, national meetings and international conferences and meetings including Canada, Malaysia, Israel, China, Pakistan, Brazil, Dubai, and Saudi Arabia.

Dr. S. Wesley Long received his MD degree in 2007 from The University of Texas Medical Branch (UTMB) in Galveston TX, where he also earned a PhD in Experimental Pathology. After finishing his doctoral studies, Dr. Long completed a clinical pathology residency at Houston Methodist. He currently serves as a member of the Editorial Board for Archives of Pathology and Laboratory Medicine. Dr. Long’s research centers on functional genomics of multidrug-resistant bacterial strains to identify novel drug targets. He is currently focusing his work on MRSA (methicillin-resistant Staphylococcus aureus) and Klebsiella pneumoniae, both of which readily acquire resistance to several different types of antibiotics and are prevalent in the hospital setting.

Overview
Dr. Matthay's overall focus is on improving clinical care of patients with acute respiratory failure from the acute respiratory distress syndrome and from sepsis. His research and clinical trials groups are very well funded by grants from the National Institute of Health. He also spends considerable time mentoring physicians and young faculty in career development and academic medicine.

Education and Training
Harvard University	A.B.	1969	English
University of Pennsylvania	M.D.	1973	School of Medicine
University of Colorado Medical Center	Internship and Residency	1976	Internal Medicine
University of California, San Francisco	Fellowship	1978	Pulmonary DIvision
University of California, San Francisco	Fellowship	1979	Cardiovascular Research Institute
 Awards and Honors
American Thoracic Society	2014		Edward Livingston Trudeau Medal
University of California, San Francisco	2013		Lifetime Achievement in Mentoring Award
University of Paris	2011		Honora Causa
American Physiologic Society	2009		Julius Comroe, Jr. Award
New York State Thoracic Society	2009		Trudeau Award

Research Goal
Our ultimate goal is to develop effective therapies that simultaneously target metabolic and vascular dysfunction in obesity and diabetes.

Current Research
Our research focuses on studies of the metabolic and vascular actions of insulin and how these actions are impaired in insulin-resistant states such as obesity, diabetes, and cardiovascular disease. Insulin-mediated microvascular recruitment plays an important role in glucose disposal and is frequently impaired in people with obesity and diabetes. We perform clinical studies that seek to understand how therapeutic interventions modulate biological actions of insulin and the molecular mechanisms of insulin resistance that play a role in coupling metabolic and vascular dysfunction in obesity and diabetes. Our research is also directed toward understanding the physiologic basis for the higher prevalence of cardiovascular dysfunction and insulin resistance in ethnic minorities such as African-Americans, Hispanic/Latinos, and Asians.

Professional Experience
Fellowship, State University of New York (SUNY), 2001鈥�2004
Residency, Wayne State University Program, 1998鈥�2001
Ph.D., Wayne State University, 1999
M.D., Bangalore Medical College, 1991

Dr. Sadis Matalon is the founding director of the Pulmonary Injury and Repair Center in the School of Medicine. He has been continuously funded by the NIH since 1978, and he is currently the principal investigator of two U01 grants and an industry grant. 

Research and Clinical Interests
Lung Injury and Repair, RSV Induced Injury to Vectorial Alveolar Na+ Transport, Chlorine Injury to the Lung, RONS and Ion Channels

Education
Graduate
University of Minnesota, Ph.D.

University of Minnesota, M.S.

Secondary Roles
Professor of Cell Biology, Physiology and Biophysics & Microbiology
Professor of Environment Health Sciences, UAB School of Public Health
Editor-in-Chief, American Journal of Physiology鈥擫ung Cellular and Molecular Physiology

My  research focuses on epithelial injury and repair, transepithelial ion transport, and ENaC-related signal pathways. We perform mechanistic preclinical and clinical studies on ALI/ARDS, COPD, asthma, and IPF.    

The laboratory of Michael J. Joyner, M.D., is interested in how humans respond to various forms of physical and mental stress during activities such as exercise, hypoxia, standing up and blood loss.

Dr. Joyner and his team study how the nervous system regulates blood pressure, heart rate and metabolism in response to these forms of stress. They are also interested in how blood flow to muscle and skin responds to these stressors. These responses are studied in young healthy subjects, healthy older subjects and people with conditions such as heart failure.

Finally, Dr. Joyner is personally interested in the role of integrative approaches in science as a powerful tool to integrate and critique data from reductionist approaches.

Focus areas
Convalescent plasma. Dr. Joyner is leading a national program sponsored by the U.S. Government to coordinate the collection and distribution of COVID-19 convalescent plasma for the treatment of individuals with severe or life-threatening disease.

Blood flow during exercise. Blood flow to exercising skeletal muscle can increase 50 to 100 times above resting values. Dr. Joyner's group is interested in the mechanisms that drive this increase in flow.

Blood pressure regulation. Blood pressure is regulated by complex interactions among the nervous system, heart and blood vessels. Dr. Joyner's group is interested in how these interactions are affected by the sex and age of the subject.

Blood glucose regulation. Glucose levels in the blood are tightly regulated to guard against hypoglycemia. Dr. Joyner and his collaborators are studying the novel idea that sensors in the body that respond to hypoxia also control blood glucose.

Breathing in heart failure. In heart failure, breathing during exercise can be excessive. Dr. Joyner and his collaborators have novel data suggesting that signals from the exercising muscle are driving ventilation in heart failure.

Physiology of elite athletes. Elite athletic performances are experiments in nature on the limits of human physiology. Dr. Joyner uses data from real-world competitions to understand the limits of human physiology.

Cognitive impairment and heart disease. Cognitive impairment is associated with risk factors for cardiovascular disease. Dr. Joyner and his collaborators are studying how aging and fitness influence brain blood vessels in humans.

Dr David Matthews is based in the Department of Cellular and Molecular Medicine at the University of Bristol鈥檚 School of Medical Sciences. He is an expert in zoonotic agents and developed key techniques to apply state of the art 鈥極mics technologies to study viruses in non-human species, notably bat lines infected with the dangerous zoonotic Hendra virus. He led the development of computational pipelines to enable large scale sequencing of Ebola virus genomes in the 2013-2015 Ebola virus epidemic in West Africa. Most recently, he was BBSRC funded to work on Middle East Respiratory Syndrome coronavirus (MERS-CoV), resulting in key research papers that informed discussions in the WHO Covid-19 steering group because of the importance to pre-clinical vaccine trials. 

Dr Matthews is one of the world鈥檚 leading academics applying high throughput approaches to study infectious disease. His primary focus is on the integration of quantitative transcriptomic and proteomic data, and on building links with clinical colleagues to gain a deeper understanding of how viral infections evolve in an individual host during infection.

Education
PhD, University of St Andrews

Jay Schnitzer is senior vice president, chief technology officer, and chief medical officer at The MITRE Corporation. In this role, he directs the organization鈥檚 independent research and development (R&D) program and manages development of corporate technology strategy, which spans MITRE鈥檚 operating centers and sponsor community. He also leads corporate and national initiatives in health and life sciences, building coalitions leveraging the best talent across the nation in these communities.

Previously, as the director of biomedical sciences at MITRE, Schnitzer oversaw the organization鈥檚 health transformation R&D program. In that capacity, he identified opportunities for MITRE to make important, transformative, and impactful differences in healthcare for our sponsors and the nation. As part of this work, he led the writing and editing of the Integrated Report for the Independent Assessment performed in response to Section 201 of the Veterans Choice Act and organized and facilitated the Blue-Ribbon Panel. To support the Department of Veterans Affairs鈥� (VA) decision on its electronic health record (EHR) system, he facilitated a special Listening Forum for the VA Secretary in August 2017, at which industry experts on EHR implementation discussed leading practices. In January 2018, he organized a panel of EHR interoperability experts, which produced a report containing recommendations as input for the VA鈥檚 contract with a commercial EHR vendor.

Before joining MITRE, Schnitzer was the director of the Defense Sciences Office at DARPA, where he led a team of 20 program managers and 70 support staff overseeing R&D across multiple domains. In addition to life sciences, biomedical research, and quantum physics, these R&D areas included materials science, advanced mathematics, and engineering. 

Formerly, Schnitzer was chief medical officer and senior vice president at Boston Scientific Corporation (BSC). His responsibilities at BSC included medical and clinical oversight of the entire product lifecycle for all medical devices manufactured by four business divisions of the company: endoscopy, urology/women鈥檚 health, neurovascular, and neuromodulation.

Prior to BSC, Schnitzer was on staff at Massachusetts General Hospital as an attending pediatric surgeon, with a joint appointment at the Shriners Hospital for Children burn center and a faculty position at Harvard Medical School.

In recognition of his work on the COVID-19 Healthcare Coalition and his leadership of the MITRE independent R&D program, WashingtonExec named Schnitzer its 2020 Healthcare Industry Executive of the Year. The award recognizes executives fostering innovation for the federal government.

Schnitzer received a B.S. degree in chemical engineering from Worcester Polytechnic Institute, a Ph.D. in chemical engineering from MIT, and an M.D. from Harvard Medical School. He is board certified and re-certified in surgery and pediatric surgery.

Dr. Susan E. Hassig has been a faculty member of the Epidemiology Department since 1996, after more than a decade of work in HIV research, surveillance, and intervention programs in the U.S. and around the globe. She has also served in the Peace Corps, where she worked to improve disease diagnosis methods and blood transfusion safety in Thailand.

Katherine Baumgarten, MD, is board certified in internal medicine and infectious diseases, and has served as Ochsner Health medical director of infection prevention since 2008. Her expertise includes health care safety and clinical infectious diseases, along with emerging infections and adult vaccines. She has been interviewed by 麻豆传媒week magazine, CNN and numerous local outlets on COVID-19, measles and bird flu, among other topics. 
Dr. Baumgarten is a fellow of both the American College of Physicians and the Infectious Diseases Society of America. She is a member of the Society for Healthcare Epidemiology of America and the American Board of Internal Medicine.
A New Orleans native, she attended Washington and Lee University in Lexington, Virginia, and earned a medical degree from Louisiana State University Health Sciences Center - New Orleans. She completed an internship and residency at the University of California at San Francisco and completed an infectious diseases fellowship at Ochsner Medical Foundation in New Orleans.

, is a professor of clinical medicine in the Department of Medicine, Division of Infectious Diseases at the University of California, San Diego. She sees patients in the Owen Clinic and the infectious diseases clinic. She also cares for people during hospital stays.
Dr. Torriani is medical director of the UC San Diego Infection Prevention and Clinical Epidemiology and the tuberculosis control units at UC San Diego Health. In collaboration with Atlas Public Health, she has been instrumental in creating an extensive electronic microbiology surveillance and pharmacy utilization program called Guardian that allows for internal data mining, surveillance, unit-specific antibiogram production, and external reporting of contagious infections to San Diego Public Health and to the California Department of Public Health (CDPH) of Healthcare Associated Infections (HAI).
Since 2010, Dr. Torriani has served on the Metrics Group for CA HAI Reporting, an independent group of experts discussing best standards and methods for HAI reporting in California. 
She is fluent in five languages: Italian, French, German, Spanish and English.